Washington 2025-2026 Regular Session

Washington Senate Bill SB5916

Introduced
1/12/26  
Refer
1/12/26  
Report Pass
1/27/26  
Engrossed
2/11/26  

Caption

AN ACT Relating to nonopioid drugs for the treatment of pain;

Impact

Implementing SB5916 could significantly affect state laws surrounding the treatment of pain in clinical settings. The bill sets forth a framework that healthcare practitioners must follow, which is expected to lead to an increase in nonopioid treatment options available to patients. This legislative move is particularly relevant considering the ongoing opioid crisis, as it aims to mitigate the associated risks of opioid dependency and overdose.

Summary

SB5916 aims to promote the use of nonopioid medications for pain management, addressing the growing concern over opioid addiction and its impact on public health. By focusing on alternative treatments, the bill seeks to reduce reliance on opioids among patients experiencing pain. This legislation specifies guidelines for healthcare providers regarding the prescription of nonopioid medications, encouraging a shift in practice patterns that prioritize safer pain management options.

Sentiment

The sentiment surrounding SB5916 appears largely positive among healthcare professionals and public health advocates who view the bill as a proactive step towards addressing the opioid epidemic. They argue that promoting nonopioid alternatives will enhance patient safety and overall healthcare outcomes. However, there may be some hesitance among certain sectors, particularly those who prescribe opioids regularly, regarding the practical implications of such a shift in prescribing practices.

Contention

There may be points of contention related to the enforcement and adherence to the guidelines established by SB5916. Critics might raise concerns about the availability and efficacy of nonopioid treatments for severe pain and how these alternatives will be integrated into existing prescribing protocols. Additionally, ensuring that healthcare providers are adequately trained and informed about nonopioid options may be a challenge that needs to be addressed in the implementation phases of the bill.

Companion Bills

No companion bills found.

Previously Filed As

WA HB1034

Concerning nonopioid drugs for the treatment of pain.

WA LR219

Interim study to examine nonopioid pharmacological treatment options in medicaid

WA LB252

Prohibit disadvantaging insurance and Medicaid coverage for nonopioid drugs

WA LR482

Interim study relating to insurance coverage practices and policies and reimbursement structures for access to nonopioid treatment options to address opioid use, overdose outcomes, and access to care across Nebraska

WA HB2383

AN ACT Relating to the involuntary treatment act;

WA SB6296

Concerning involuntary treatment.

WA HB2196

Revised for 1st substitute: Expanding access to PANDA PANS treatment.

WA SB5353

Concerning the diabetes prevention and obesity treatment act.

WA HB1326

AN ACT Relating to the diabetes prevention and obesity treatment act;

WA SB974

Maryland Medical Assistance Program and Health Insurance - Nonopioid Drugs for the Treatment of Pain

Similar Bills

No similar bills found.